Showing results (1-10 of 78) with videos related to
Sort By:
Pageof 8
Oncoimmunology|December 20, 2013
Is there a future for adoptive cell transfer in melanoma patients?Michal J BesserAmerican Journal of Clinical Dermatology|March 22, 2013
Immunotherapy for the management of advanced melanoma: the next stepsDragoslav Zikich, Jacob Schachter, Michal J BesserImmunotherapy|December 15, 2015
Predictors of tumor-infiltrating lymphocyte efficacy in melanomaDragoslav Zikich, Jacob Schachter, Michal J BesserJournal of Neuroimmunology|September 10, 2005
Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or bothMichal J Besser, Yonatan Ganor, Mia LeviteCancer Journal (Sudbury, Mass.)|November 21, 2015
Tumor-Infiltrating Lymphocytes: Clinical ExperienceMichal J Besser, Ronnie Shapira-Frommer, Jacob SchachterAmerican Journal of Cancer Research|September 9, 2020
ADAR1 regulates melanoma cell invasiveness by controlling beta3-integrin via microRNA-30 family membersYael Nemlich, Michal J Besser, Jacob Schachter, et al.Clinical & Developmental Immunology|January 15, 2011
Focus on adoptive T cell transfer trials in melanomaLiat Hershkovitz, Jacob Schachter, Avraham J Treves, et al.European Radiology|March 26, 2014
CT halo sign as an imaging marker for response to adoptive cell therapy in metastatic melanoma with pulmonary metastasesShai Shrot, Jacob Schachter, Ronnie Shapira-Frommer, et al.Frontiers in Oncology|March 20, 2023
Modulating the proliferative and cytotoxic properties of patient-derived TIL by a synthetic immune niche of immobilized CCL21 and ICAM1Sharon Yunger, Benjamin Geiger, Nir Friedman, et al.Cancer Journal (Sudbury, Mass.)|January 24, 2017
Adoptive Cell Therapy for Metastatic MelanomaEfrat Merhavi-Shoham, Orit Itzhaki, Gal Markel, et al.Pageof 8